AliveDx Showcases MosaiQ and LumiQ Systems at ADLM 2026
Posted on 29 Jul 2026
AliveDx is showcasing diagnostic solutions for autoimmune disease, allergy, and transfusion medicine at ADLM 2026, held July 28–30 at the Anaheim Convention Center in California. At booth 4337, visitors can explore platforms designed to shorten time to results, provide clinical insights, and improve laboratory workflows.
A central feature of the exhibit is MosaiQ, AliveDx’s fully automated, high-throughput platform for syndromic multiplex testing. The system combines microarray technology with automated laboratory workflows to enable the simultaneous analysis of multiple markers.
The company is also presenting LumiQ, a compact, all-in-one platform for indirect immunofluorescence assay testing in autoimmune diagnostics. LumiQ automates the workflow from sample processing through image capture, reading, and interpretation to help laboratories standardize IFA testing.
AliveDx is additionally highlighting scientific evidence supporting the performance of MosaiQ assays across vasculitis, autoimmune rheumatic diseases, and celiac disease. Three studies are being presented during the Clinical and Diagnostic Immunology poster session on July 29.
One poster evaluates a multiplex microarray immunoassay for the simultaneous detection of anti-MPO, anti-PR3, and anti-GBM autoantibodies. A second examines the detection of 15 autoantibodies associated with autoimmune rheumatic diseases, while the third compares the clinical performance of a multiplexed microarray immunoassay for celiac disease autoantibodies in a pediatric population.
Through its ADLM 2026 exhibit, AliveDx is demonstrating how automated multiplex and immunofluorescence technologies can help laboratories consolidate workflows, improve standardization, and provide faster diagnostic information.
